Sentences with phrase «drugs in cancer cells»

«We've also started exchanging ideas and information with scientists facing related challenges, such as resistance to herbicides in weeds and resistance to drugs in cancer cells,» Tabashnik said.

«The advanced nano - focussed x-ray beam at ESRF has not only allowed us to locate the site of action of our novel Organo - Osmium FY26 candidate drug in cancer cells at unprecedented resolution, but also study the movement of natural metals such as zinc and calcium in cells.

Not exact matches

Kite Pharma, one of the companies chasing a new generation of cancer drugs called chimeric antigen receptor T - cell (CAR - T) therapies, announced a patient death in a clinical trial of its experimental KTE - C19.

This drug has already staked its claim in the world of next - gen «checkpoint inhibitor» cancer treatments by besting rival Bristol - Myers Squibb's competing treatment Opdivo in advanced non-small cell lung cancer (NSCLC).

One recent example: Stemcentrx, which rode an unproven approach targeting cancer stem cells to a summertime financing round of nearly $ 250 million and a $ 5 billion valuation, the most for a venture - backed drug maker and second to Theranos in health care.

Speaking of Novartis — the company's experimental CTL019, which is expected to be the first approved drug in a revolutionary new cancer treatment space that turns the body's own immune cells into cancer - killers, is already facing some apprehension from doctors and patient groups who are worried about its eventual pricing.

BMS's drug, ipilimumab (Yervoy), was the first checkpoint inhibitor (a kind of cancer immunotherapy drug that essentially helps the immune system release its brake and go after tumor cells it might normally miss) to get approved in the US in 2011 for melanoma.

Swiss pharmaceutical giant Novartis has made waves with a drug pipeline that includes one of the most talked - about experimental cancer therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.

giant Novartis has made waves with a drug pipeline that includes one of the most talked - about experimental cancer therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.

In the second half of 2017, the United States Food and Drug Administration (FDA) approved two immunotherapies that use genetically engineered T cells (CAR - T cell therapy) to fight cancer.

The drug helps boost red blood cells in cancer patients.

They'll also jointly market Pfizer's drug Xalkori, which is approved in more than 75 countries for treating non-small cell lung cancer in patients with a certain genetic mutation.

Immune oncology drugs use a mechanism to enable the immune system to «uncloak» hidden cancer cells in the body and then attack them.

Cambridge, MA — February 6, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (OM).

Investigators have repeatedly touted the drug as a potential lynchpin in immuno - oncology, focusing on an enzyme that suppresses the immune cells Opdivo and a whole new class of PD - 1 / L1 checkpoints are designed to unleash in an attack on cancer cells.

Her doctor suggested Erbitux — a proven cancer drug that targets cancer cells exclusively, unlike conventional chemotherapies that more crudely kill all fast - growing cells in the body — and Aucoin went to a clinic to begin treatment.

DMBA is another cancer - generating drug used in research because it causes mutations in cells.

Cyclophosphamide, Doxorubicin, and most chemotherapy drugs for cancer — these drugs kill cells in the mother's body and may harm the baby.

Most Chemotherapy Drugs for Cancer: Since they kill cells in the mother's body, they may harm the baby as well.

Breech Twins and higher order multiples Previous CS Pre-Eclampsia Placenta praevia Cervical incompetence Previous late stillbirth Previous premature birth Grand multiparty Age under 18 Age over 35 Smoking Drug use Severe mental health issue Epilepsy Type 1 diabetes Type 2 diabetes Gestational diabetes Asthma GBS positive Abnormal antibodies Transplant recipient Congenital heart disease Known foetal abnormality Immunosuppressive medication MS Physical disability Intellectual disability Hypothyroidism Hyperthyroidism Previous shoulder dystocia Previous 3rd or 4th degree tear Sickle Cell anaemia BMI under 18 or over 35 at conception Previous massive PPH APH in current pregnancy HIV / AIDS Hepatitis B or C Active TB IUGR Oligohydramnios Polyhydramnios Child previously removed from custody because of abuse Uterine abnormalities such as uterine septum or double uterus Previous uterine surgery for fibroids Chronic renal problems Hypertension Auto immune condition Previous stroke or blod clot Cancer Domestic violence or abusive home Prisoners Homeless women

(borrowed from Dr Kitty) Breech Twins and higher order multiples Previous CS Pre-Eclampsia Placenta praevia Cervical incompetence Previous late stillbirth Previous premature birth Grand multiparty Age under 18 Age over 35 Smoking Drug use Severe mental health issue Epilepsy Type 1 diabetes Type 2 diabetes Gestational diabetes Asthma GBS positive Abnormal antibodies Transplant recipient Congenital heart disease Known foetal abnormality Immunosuppressive medication MS Physical disability Intellectual disability Hypothyroidism Hyperthyroidism Previous shoulder dystocia Previous 3rd or 4th degree tear Sickle Cell anaemia BMI under 18 or over 35 at conception Previous massive PPH APH in current pregnancy HIV / AIDS Hepatitis B or C Active TB IUGR Oligohydramnios Polyhydramnios Child previously removed from custody because of abuse Uterine abnormalities such as uterine septum or double uterus Previous uterine surgery for fibroids Chronic renal problems Hypertension Auto immune condition Previous stroke or blod clot Cancer Domestic violence or abusive home Prisoners Homeless women

«This phase III trial will be noteworthy for being the first prostate cancer trial to assess a biomarker, namely AR - V7 in circulating tumour cells, as a predictor of response at the same time as testing the efficacy of the drug,» Prof Taplin will conclude.

In November 2010 Japanese researchers announced online in Analytical Chemistry that they had built a chip that simultaneously tests how liver, intestine and breast cancer cells respond to cancer drugs, and in February 2010 scientists publishing in the Proceedings of the National Academy of Sciences USA developed a microscale replica of the human liver that allowed them to observe the entire life cycle of hepatitis C, a virus that is difficult to observe in cultured cellIn November 2010 Japanese researchers announced online in Analytical Chemistry that they had built a chip that simultaneously tests how liver, intestine and breast cancer cells respond to cancer drugs, and in February 2010 scientists publishing in the Proceedings of the National Academy of Sciences USA developed a microscale replica of the human liver that allowed them to observe the entire life cycle of hepatitis C, a virus that is difficult to observe in cultured cellin Analytical Chemistry that they had built a chip that simultaneously tests how liver, intestine and breast cancer cells respond to cancer drugs, and in February 2010 scientists publishing in the Proceedings of the National Academy of Sciences USA developed a microscale replica of the human liver that allowed them to observe the entire life cycle of hepatitis C, a virus that is difficult to observe in cultured cellin February 2010 scientists publishing in the Proceedings of the National Academy of Sciences USA developed a microscale replica of the human liver that allowed them to observe the entire life cycle of hepatitis C, a virus that is difficult to observe in cultured cellin the Proceedings of the National Academy of Sciences USA developed a microscale replica of the human liver that allowed them to observe the entire life cycle of hepatitis C, a virus that is difficult to observe in cultured cellin cultured cells.

«Because this binding causes EphA2 internalization, we also sought to conjugate 123B9 with paclitaxel and thus direct the drug to migrating cancer cells,» said Pellecchia, who holds the Daniel Hays Chair in Cancer Research acancer cells,» said Pellecchia, who holds the Daniel Hays Chair in Cancer Research aCancer Research at UCR.

Now, though, new drugs that disable these checkpoint proteins are showing a keen ability to awaken T cells and, in so doing, pull away cancer's veil.

These results significantly advance understanding of how cancer cells are made to move during metastasis and may provide more precise targets for drugs to stop cancer metastasis in patients where there are oncogenic mutations.

«Used in cancer therapy, this process could increase the impact of a treatment by heating the cancer cells while introducing the drug compound into the tumor.»

«The fine particles of this drug allow for it to be released slowly and stay in the abdomen,» said Katherine Roby, Ph.D., research associate professor in the Department of Anatomy and Cell Biology at KU Medical Cancer, who started her pre-clinical work on Nanotax more than a decade ago.

Jeffrey Settleman of the Massachusetts General Hospital Cancer Center in Charlestown and his colleagues treated tumour cells with cancer Cancer Center in Charlestown and his colleagues treated tumour cells with cancer cancer drugs.

For some years now, a new class of drugs called antibody - drug conjugates (ADCs) have been used, which work in two ways: they consist of an antibody that binds selectively to the tumor cell receptor and interrupts the signal to propagate; they also act as a transport vehicle for a chemical substance that enters the cancer cells with the antibody and triggers their death.

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Hcancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HeaCell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HeaCell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Heacell research at Moores Cancer Center at UC San Diego HCancer Center at UC San Diego Health.

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells» resistance to paclitaxel.

«The concentration of the drug stays higher in the space where the cancer is, killing more cancer cells.

Dr. McCabe said nanoparticles are a leading - edge technology also being studied for delivery of drugs for other conditions, such as cancer, heart disease, and bacterial infections, in order to target specific cells to reduce toxicity and side effects of those medications and to make them more effective.

In a head - to - head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous - non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.

But Whitehead Institute researchers have found a mechanism underlying this resistance — a mechanism that naturally occurs in many diverse cancer types and that may expose vulnerabilities to drugs that spur the natural cell - death process.

An experimental drug in early development for aggressive brain tumors can cross the blood - brain tumor barrier, kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).

Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in Cancer Discovery, a journal of the American Association for Cancer Rescancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in Cancer Discovery, a journal of the American Association for Cancer ResCancer Discovery, a journal of the American Association for Cancer ResCancer Research.

Daniel Chen, a postdoc in Dogic's lab, imagines that someday the droplets could be controlled to deliver drugs or seek out cancer cells.

Schwarz and her colleagues used three different drugs, alone and in combination, to deprive cervical tumors of glucose and block downstream metabolic pathways that help protect cancer cells from building up toxic free radicals.

While researchers have long worked with nanoparticles for drug delivery, the findings put forth by He and his team represent a crucial breakthrough in addressing multidrug resistance in cancer cells.

For some cancer patients, viruses engineered to zero in on tumor cells work like a wonder drug.

«Breakthrough technique combats cancer drug resistance: Researchers «turn off» multi-drug resistance capabilities in cancer cells.»

The researchers found that, in response to the maximum tolerated doses of several commonly used chemotherapy drugs, breast cancer - associated fibroblasts secrete large amounts of cell signaling proteins called ELR + chemokines.

One class of immunotherapeutic drugs is known as «checkpoint» inhibitors, as they target checkpoints in immune system regulation to allow the body's natural defenses, such as white blood cells, to more effectively target the cancer.

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arcancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, ArCancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

The researchers also used their ultrasound technique in mice to image Salmonella bacteria, which could be used to deliver cancer - killing drugs to tumor cells.

In addition, a drug called dexrazoxane that could reduce cell damage has recently been approved for patients with metastatic breast cancer who receive high doses of doxorubicin.

However, along with this seemingly linear storyline in which retinoids block progesterone's promotion of CK5 + cells, previous work in the lab of CU Cancer Center investigator Peter Kabos, MD, and others shows that breast cancers treated with anti-estrogen drugs like tamoxifen or aromatase inhibitors show an increased population of CK5 + cells — it is as if these therapies remove the roadblock of estrogen - dependent cells, leaving CK5 + cells to proliferate.

Das explained that since the compounds they've developed make cancer cells more sensitive to attack, they also remove resistance to standard chemotherapy drugs — a serious problem in current therapies.